Table 10 Overexpression of TPX2 promotes the resistance and knockdown of TPX2 enhances the sensitivity of HepG2 cells to antitumor drugs, TKIs and chemotherapies.
Antitumor drugs | Control | TPX2 | siTPX2 |
|---|---|---|---|
IC50 values (μmol/L) | |||
sorafenib | 1.27 (0.82–1.75) | 4.68 (3.90–4.83) | 0.50 (0.34–0.58) |
lenvatinib | 1.30 (0.75–1.63) | 5.89 (5.66–6.71) | 0.33 (0.20–0.60) |
regorafenib | 1.01 (0.66–1.26) | 3.65 (3.10–3.84) | 0.62 (0.45–0.78) |
cabozantinib | 0.88(0.73–1.35) | 4.78 (4.21–4.99) | 0.39 (0.30–0.59) |
doxorubicin | 0.33 (0.06–0.48) | 1.59 (1.36–1.80) | 0.05 (0.03–0.07) |
paclitaxel | 14.78 (10.12–18.33) (nmol/L) | 0.24 (0.18–0.37) (μmol/L) | 8.31 (5.00–9.25) (nmol/L) |
etoposide | 0.46 (0.27–0.56) | 1.93 (1.76–2.28) | 0.18 (0.09–0.23) |
irinotecan | 0.30 (0.28–0.40) | 0.82(0.73–0.93) | 0.10 (0.08–0.15) |
